한글목차

개요

지연성운동장애 치료 시장은 2023-20281년에 6억 3,245만 달러, 예측 기간 중 CAGR은 4.73%로 성장할 것으로 예측됩니다.

지연성운동장애 치료 시장의 전체적인 분석, 시장 규모·예측, 동향, 성장 촉진요인, 과제, 약 25개 벤더를 다룬 벤더 분석 등을 제공합니다.

현재의 시장 시나리오, 최신 동향과 촉진요인, 시장 환경 전체에 관한 최신 분석을 제공하고 있습니다. 시장은 정신장애 환자의 증가, 항정신병약 처방의 증가, 신경질환 치료에 대한 방대한 미충족 요구에 의해 촉진되고 있습니다.

본 조사에서는 지연성운동장애의 치료에 관한 인식을 넓히는 구상이 향후 수년간 지연성운동장애 치료 시장 성장을 촉진하는 주요인의 하나로 식별되고 있습니다. 또한 지연성운동장애의 치료에 대한 규제기관 승인이 진행되고, 제약기업에 의한 연구 자금이 증가하고 있는 것도 이 시장의 큰 수요로 연결될 것으로 생각됩니다.

목차

제1장 주요 요약

• 시장 개요

제2장 시장 구도

• 시장 에코시스템

제3장 시장 규모 파악

• 시장의 정의
• 시장 부문 분석
• 시장 규모 2023
• 시장 전망 2023-2028

제4장 시장 규모 실적

• 세계의 지연성운동장애 치료 시장 2018-2022
• 최종사용자 부문 분석 2018-2022
• 제품 부문 분석 2018-2022
• 지역별 부문 분석 2018-2022
• 국가별 부문 분석 2018-2022

제5장 Five forces 분석

• Five Forces 요약
• 구매자의 교섭력
• 공급 기업의 교섭력
• 신규 진출업체의 위협
• 대체품의 위협
• 경쟁의 위협
• 시장 현황

제6장 시장 세분화 : 최종사용자별

• 시장 부문
• 비교 : 최종사용자별
• 병원 약국 : 시장 규모와 예측 2023-2028
• 소매 약국 : 시장 규모와 예측 2023-2028
• 온라인 약국 : 시장 규모와 예측 2023-2028
• 시장 기회 : 최종사용자별

제7장 시장 세분화 : 제품별

• 시장 부문
• 비교 : 제품별
• Austedo 및 Ingrezza : 시장 규모와 예측 2023-2028
• Amantadine 등 : 시장 규모와 예측 2023-2028
• 시장 기회 : 제품별

제8장 고객 상황

• 고객 상황의 개요

제9장 지역별 상황

• 지역별 세분화
• 지역별 비교
• 북미 : 시장 규모와 예측 2023-2028
• 유럽 : 시장 규모와 예측 2023-2028
• 아시아 : 시장 규모와 예측 2023-2028
• 세계의 기타 지역 : 시장 규모와 예측 2023-2028
• 미국 : 시장 규모와 예측 2023-2028
• 독일 : 시장 규모와 예측 2023-2028
• 영국 : 시장 규모와 예측 2023-2028
• 중국 : 시장 규모와 예측 2023-2028
• 프랑스 : 시장 규모와 예측 2023-2028
• 시장 기회 : 지역 상황별

제10장 촉진요인, 과제 및 동향

• 시장 촉진요인
• 시장이 해결해야 할 과제
• 촉진요인과 과제의 영향
• 시장 동향

제11장 벤더 구도

• 개요
• 벤더 구도
• 혼란의 상황
• 업계의 리스크

제12장 벤더 분석

• 대상 벤더
• 벤더의 시장 포지셔닝
• Abbott Laboratories
• Alembic Pharmaceuticals Ltd.
• Aspire Pharma Ltd.
• Centaur Pharmaceuticals Pvt. Ltd.
• Cipla Ltd.
• Lannett Co. Inc.
• Luye Pharma Group Ltd.
• Neurocrine Biosciences Inc.
• Novartis AG
• Psicofarma S. A. de C. V
• Sawai Group Holdings Co. Ltd.
• SOM Innovation Biotech S.A.
• SteriMax Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.

제13장 부록

영문목차

Abstract

The tardive dyskinesia treatment market is forecasted to grow by USD 632.45 mn during 2023-2028, accelerating at a CAGR of 4.73% during the forecast period. The report on the tardive dyskinesia treatment market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising cases of mental disorders, growing antipsychotic prescription, and huge unmet need for neurological disease treatments.

Technavio's tardive dyskinesia treatment market is segmented as below:

By End-user

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy

By Product

• Austedo and lngrezza
• Amantadine
• Others

By Geographical Landscape

• North America
• Europe
• Asia
• Rest of World (ROW)

This study identifies the initiatives to spread awareness regarding treatment of tardive dyskinesia as one of the prime reasons driving the tardive dyskinesia treatment market growth during the next few years. Also, growing regulatory approval for treating tardive dyskinesia and increasing research funding by pharmaceutical companies will lead to sizable demand in the market.

The report on the tardive dyskinesia treatment market covers the following areas:

• Tardive dyskinesia treatment market sizing
• Tardive dyskinesia treatment market forecast
• Tardive dyskinesia treatment market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading tardive dyskinesia treatment market vendors that include Abbott Laboratories, Actiza Pharmaceutical Pvt. Ltd., Alembic Pharmaceuticals Ltd., Aspire Pharma Ltd., Centaur Pharmaceuticals Pvt. Ltd., Cipla Ltd., Hetero Labs Ltd., Lannett Co. Inc., Luye Pharma Group Ltd., Neurocrine Biosciences Inc., Novartis AG, Psicofarma S. A. de C. V, Ryon pharma, Sawai Group Holdings Co. Ltd., Slate Run Pharmaceuticals LLC, Solco Healthcare, SOM Innovation Biotech S.A., SteriMax Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.. Also, the tardive dyskinesia treatment market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
• Exhibit 01: Executive Summary - Chart on Market Overview
• Exhibit 02: Executive Summary - Data Table on Market Overview
• Exhibit 03: Executive Summary - Chart on Global Market Characteristics
• Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
• Exhibit 05: Executive Summary - Chart on Market Segmentation by End-user
• Exhibit 06: Executive Summary - Chart on Market Segmentation by Product
• Exhibit 07: Executive Summary - Chart on Incremental Growth
• Exhibit 08: Executive Summary - Data Table on Incremental Growth
• Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition
• Exhibit 12: Offerings of vendors included in the market definition
• 3.2 Market segment analysis
• Exhibit 13: Market segments
• 3.3 Market size 2023
• 3.4 Market outlook: Forecast for 2023-2028
• Exhibit 14: Chart on Global - Market size and forecast 2023-2028 ($ million)
• Exhibit 15: Data Table on Global - Market size and forecast 2023-2028 ($ million)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

• 4.1 Global tardive dyskinesia treatment market 2018 - 2022
• Exhibit 18: Historic Market Size - Data Table on global tardive dyskinesia treatment market 2018 - 2022 ($ million)
• 4.2 End-user Segment Analysis 2018 - 2022
• Exhibit 19: Historic Market Size - End-user Segment 2018 - 2022 ($ million)
• 4.3 Product Segment Analysis 2018 - 2022
• Exhibit 20: Historic Market Size - Product Segment 2018 - 2022 ($ million)
• 4.4 Geography Segment Analysis 2018 - 2022
• Exhibit 21: Historic Market Size - Geography Segment 2018 - 2022 ($ million)
• 4.5 Country Segment Analysis 2018 - 2022
• Exhibit 22: Historic Market Size - Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

• 5.1 Five forces summary
• Exhibit 23: Five forces analysis - Comparison between 2023 and 2028
• 5.2 Bargaining power of buyers
• Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
• 5.3 Bargaining power of suppliers
• Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
• 5.4 Threat of new entrants
• Exhibit 26: Threat of new entrants - Impact of key factors in 2023 and 2028
• 5.5 Threat of substitutes
• Exhibit 27: Threat of substitutes - Impact of key factors in 2023 and 2028
• 5.6 Threat of rivalry
• Exhibit 28: Threat of rivalry - Impact of key factors in 2023 and 2028
• 5.7 Market condition
• Exhibit 29: Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by End-user

• 6.1 Market segments
• Exhibit 30: Chart on End-user - Market share 2023-2028 (%)
• Exhibit 31: Data Table on End-user - Market share 2023-2028 (%)
• 6.2 Comparison by End-user
• Exhibit 32: Chart on Comparison by End-user
• Exhibit 33: Data Table on Comparison by End-user
• 6.3 Hospital pharmacy - Market size and forecast 2023-2028
• Exhibit 34: Chart on Hospital pharmacy - Market size and forecast 2023-2028 ($ million)
• Exhibit 35: Data Table on Hospital pharmacy - Market size and forecast 2023-2028 ($ million)
• Exhibit 36: Chart on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
• Exhibit 37: Data Table on Hospital pharmacy - Year-over-year growth 2023-2028 (%)
• 6.4 Retail pharmacy - Market size and forecast 2023-2028
• Exhibit 38: Chart on Retail pharmacy - Market size and forecast 2023-2028 ($ million)
• Exhibit 39: Data Table on Retail pharmacy - Market size and forecast 2023-2028 ($ million)
• Exhibit 40: Chart on Retail pharmacy - Year-over-year growth 2023-2028 (%)
• Exhibit 41: Data Table on Retail pharmacy - Year-over-year growth 2023-2028 (%)
• 6.5 Online pharmacy - Market size and forecast 2023-2028
• Exhibit 42: Chart on Online pharmacy - Market size and forecast 2023-2028 ($ million)
• Exhibit 43: Data Table on Online pharmacy - Market size and forecast 2023-2028 ($ million)
• Exhibit 44: Chart on Online pharmacy - Year-over-year growth 2023-2028 (%)
• Exhibit 45: Data Table on Online pharmacy - Year-over-year growth 2023-2028 (%)
• 6.6 Market opportunity by End-user
• Exhibit 46: Market opportunity by End-user ($ million)
• Exhibit 47: Data Table on Market opportunity by End-user ($ million)

7 Market Segmentation by Product

• 7.1 Market segments
• Exhibit 48: Chart on Product - Market share 2023-2028 (%)
• Exhibit 49: Data Table on Product - Market share 2023-2028 (%)
• 7.2 Comparison by Product
• Exhibit 50: Chart on Comparison by Product
• Exhibit 51: Data Table on Comparison by Product
• 7.3 Austedo and Ingrezza - Market size and forecast 2023-2028
• Exhibit 52: Chart on Austedo and Ingrezza - Market size and forecast 2023-2028 ($ million)
• Exhibit 53: Data Table on Austedo and Ingrezza - Market size and forecast 2023-2028 ($ million)
• Exhibit 54: Chart on Austedo and Ingrezza - Year-over-year growth 2023-2028 (%)
• Exhibit 55: Data Table on Austedo and Ingrezza - Year-over-year growth 2023-2028 (%)
• 7.4 Amantadine and others - Market size and forecast 2023-2028
• Exhibit 56: Chart on Amantadine and others - Market size and forecast 2023-2028 ($ million)
• Exhibit 57: Data Table on Amantadine and others - Market size and forecast 2023-2028 ($ million)
• Exhibit 58: Chart on Amantadine and others - Year-over-year growth 2023-2028 (%)
• Exhibit 59: Data Table on Amantadine and others - Year-over-year growth 2023-2028 (%)
• 7.5 Market opportunity by Product
• Exhibit 60: Market opportunity by Product ($ million)
• Exhibit 61: Data Table on Market opportunity by Product ($ million)

8 Customer Landscape

• 8.1 Customer landscape overview
• Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation
• Exhibit 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
• Exhibit 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
• 9.2 Geographic comparison
• Exhibit 65: Chart on Geographic comparison
• Exhibit 66: Data Table on Geographic comparison
• 9.3 North America - Market size and forecast 2023-2028
• Exhibit 67: Chart on North America - Market size and forecast 2023-2028 ($ million)
• Exhibit 68: Data Table on North America - Market size and forecast 2023-2028 ($ million)
• Exhibit 69: Chart on North America - Year-over-year growth 2023-2028 (%)
• Exhibit 70: Data Table on North America - Year-over-year growth 2023-2028 (%)
• 9.4 Europe - Market size and forecast 2023-2028
• Exhibit 71: Chart on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibit 72: Data Table on Europe - Market size and forecast 2023-2028 ($ million)
• Exhibit 73: Chart on Europe - Year-over-year growth 2023-2028 (%)
• Exhibit 74: Data Table on Europe - Year-over-year growth 2023-2028 (%)
• 9.5 Asia - Market size and forecast 2023-2028
• Exhibit 75: Chart on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibit 76: Data Table on Asia - Market size and forecast 2023-2028 ($ million)
• Exhibit 77: Chart on Asia - Year-over-year growth 2023-2028 (%)
• Exhibit 78: Data Table on Asia - Year-over-year growth 2023-2028 (%)
• 9.6 Rest of World (ROW) - Market size and forecast 2023-2028
• Exhibit 79: Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibit 80: Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
• Exhibit 81: Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• Exhibit 82: Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
• 9.7 US - Market size and forecast 2023-2028
• Exhibit 83: Chart on US - Market size and forecast 2023-2028 ($ million)
• Exhibit 84: Data Table on US - Market size and forecast 2023-2028 ($ million)
• Exhibit 85: Chart on US - Year-over-year growth 2023-2028 (%)
• Exhibit 86: Data Table on US - Year-over-year growth 2023-2028 (%)
• 9.8 Germany - Market size and forecast 2023-2028
• Exhibit 87: Chart on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibit 88: Data Table on Germany - Market size and forecast 2023-2028 ($ million)
• Exhibit 89: Chart on Germany - Year-over-year growth 2023-2028 (%)
• Exhibit 90: Data Table on Germany - Year-over-year growth 2023-2028 (%)
• 9.9 UK - Market size and forecast 2023-2028
• Exhibit 91: Chart on UK - Market size and forecast 2023-2028 ($ million)
• Exhibit 92: Data Table on UK - Market size and forecast 2023-2028 ($ million)
• Exhibit 93: Chart on UK - Year-over-year growth 2023-2028 (%)
• Exhibit 94: Data Table on UK - Year-over-year growth 2023-2028 (%)
• 9.10 China - Market size and forecast 2023-2028
• Exhibit 95: Chart on China - Market size and forecast 2023-2028 ($ million)
• Exhibit 96: Data Table on China - Market size and forecast 2023-2028 ($ million)
• Exhibit 97: Chart on China - Year-over-year growth 2023-2028 (%)
• Exhibit 98: Data Table on China - Year-over-year growth 2023-2028 (%)
• 9.11 France - Market size and forecast 2023-2028
• Exhibit 99: Chart on France - Market size and forecast 2023-2028 ($ million)
• Exhibit 100: Data Table on France - Market size and forecast 2023-2028 ($ million)
• Exhibit 101: Chart on France - Year-over-year growth 2023-2028 (%)
• Exhibit 102: Data Table on France - Year-over-year growth 2023-2028 (%)
• 9.12 Market opportunity By Geographical Landscape
• Exhibit 103: Market opportunity By Geographical Landscape ($ million)
• Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ million)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers
• 10.2 Market challenges
• 10.3 Impact of drivers and challenges
• Exhibit 105: Impact of drivers and challenges in 2023 and 2028
• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview
• 11.2 Vendor landscape
• Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
• 11.3 Landscape disruption
• Exhibit 107: Overview on factors of disruption
• 11.4 Industry risks
• Exhibit 108: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered
• Exhibit 109: Vendors covered
• 12.2 Market positioning of vendors
• Exhibit 110: Matrix on vendor position and classification
• 12.3 Abbott Laboratories
• Exhibit 111: Abbott Laboratories - Overview
• Exhibit 112: Abbott Laboratories - Business segments
• Exhibit 113: Abbott Laboratories - Key news
• Exhibit 114: Abbott Laboratories - Key offerings
• Exhibit 115: Abbott Laboratories - Segment focus
• 12.4 Alembic Pharmaceuticals Ltd.
• Exhibit 116: Alembic Pharmaceuticals Ltd. - Overview
• Exhibit 117: Alembic Pharmaceuticals Ltd. - Product / Service
• Exhibit 118: Alembic Pharmaceuticals Ltd. - Key offerings
• 12.5 Aspire Pharma Ltd.
• Exhibit 119: Aspire Pharma Ltd. - Overview
• Exhibit 120: Aspire Pharma Ltd. - Product / Service
• Exhibit 121: Aspire Pharma Ltd. - Key offerings
• 12.6 Centaur Pharmaceuticals Pvt. Ltd.
• Exhibit 122: Centaur Pharmaceuticals Pvt. Ltd. - Overview
• Exhibit 123: Centaur Pharmaceuticals Pvt. Ltd. - Product / Service
• Exhibit 124: Centaur Pharmaceuticals Pvt. Ltd. - Key offerings
• 12.7 Cipla Ltd.
• Exhibit 125: Cipla Ltd. - Overview
• Exhibit 126: Cipla Ltd. - Business segments
• Exhibit 127: Cipla Ltd. - Key news
• Exhibit 128: Cipla Ltd. - Key offerings
• Exhibit 129: Cipla Ltd. - Segment focus
• 12.8 Lannett Co. Inc.
• Exhibit 130: Lannett Co. Inc. - Overview
• Exhibit 131: Lannett Co. Inc. - Product / Service
• Exhibit 132: Lannett Co. Inc. - Key offerings
• 12.9 Luye Pharma Group Ltd.
• Exhibit 133: Luye Pharma Group Ltd. - Overview
• Exhibit 134: Luye Pharma Group Ltd. - Business segments
• Exhibit 135: Luye Pharma Group Ltd. - Key offerings
• Exhibit 136: Luye Pharma Group Ltd. - Segment focus
• 12.10 Neurocrine Biosciences Inc.
• Exhibit 137: Neurocrine Biosciences Inc. - Overview
• Exhibit 138: Neurocrine Biosciences Inc. - Product / Service
• Exhibit 139: Neurocrine Biosciences Inc. - Key offerings
• 12.11 Novartis AG
• Exhibit 140: Novartis AG - Overview
• Exhibit 141: Novartis AG - Business segments
• Exhibit 142: Novartis AG - Key offerings
• Exhibit 143: Novartis AG - Segment focus
• 12.12 Psicofarma S. A. de C. V
• Exhibit 144: Psicofarma S. A. de C. V - Overview
• Exhibit 145: Psicofarma S. A. de C. V - Product / Service
• Exhibit 146: Psicofarma S. A. de C. V - Key offerings
• 12.13 Sawai Group Holdings Co. Ltd.
• Exhibit 147: Sawai Group Holdings Co. Ltd. - Overview
• Exhibit 148: Sawai Group Holdings Co. Ltd. - Product / Service
• Exhibit 149: Sawai Group Holdings Co. Ltd. - Key offerings
• 12.14 SOM Innovation Biotech S.A.
• Exhibit 150: SOM Innovation Biotech S.A. - Overview
• Exhibit 151: SOM Innovation Biotech S.A. - Product / Service
• Exhibit 152: SOM Innovation Biotech S.A. - Key offerings
• 12.15 SteriMax Inc.
• Exhibit 153: SteriMax Inc. - Overview
• Exhibit 154: SteriMax Inc. - Product / Service
• Exhibit 155: SteriMax Inc. - Key offerings
• 12.16 Sun Pharmaceutical Industries Ltd.
• Exhibit 156: Sun Pharmaceutical Industries Ltd. - Overview
• Exhibit 157: Sun Pharmaceutical Industries Ltd. - Product / Service
• Exhibit 158: Sun Pharmaceutical Industries Ltd. - Key offerings
• 12.17 Teva Pharmaceutical Industries Ltd.
• Exhibit 159: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 160: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 161: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 162: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 163: Teva Pharmaceutical Industries Ltd. - Segment focus

13 Appendix

• 13.1 Scope of the report
• 13.2 Inclusions and exclusions checklist
• Exhibit 164: Inclusions checklist
• Exhibit 165: Exclusions checklist
• 13.3 Currency conversion rates for US$
• Exhibit 166: Currency conversion rates for US$
• 13.4 Research methodology
• Exhibit 167: Research methodology
• Exhibit 168: Validation techniques employed for market sizing
• Exhibit 169: Information sources
• 13.5 List of abbreviations
• Exhibit 170: List of abbreviations